Stay updated on Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial
Sign up to get notified when there's something new on the Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial page.

Latest updates to the Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial page
- Check7 days agoChange DetectedThe page no longer lists 'Type 2 diabetes' as a condition and removes the related topic 'MedlinePlus Genetics'.SummaryDifference0.2%

- Check14 days agoChange DetectedRevision: v3.4.2 was added to the page, and the temporary government funding/operating status notice was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check21 days agoChange DetectedThe page now displays a general government funding notice and a site revision update: Revision: v3.4.1 replacing v3.4.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check28 days agoChange DetectedShow glossary option and related topics (Type 2 diabetes, MedlinePlus Genetics) were added. QC-related metadata labels were updated to include 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0', while older labels such as 'Last Update Submitted that met QC Criteria', 'No FEAR Act data' and 'Revision: v3.3.4' were removed or adjusted.SummaryDifference0.4%

- Check35 days agoChange DetectedThe page lost its Type 2 diabetes topic tags and related topics such as MedlinePlus Genetics, removing key subject metadata and potentially reducing discoverability.SummaryDifference0.2%

- Check42 days agoChange DetectedThe page now shows Revision: v3.3.4 instead of v3.3.3; this update does not change any study details, eligibility, or outcomes.SummaryDifference0.1%

Stay in the know with updates to Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ipragliflozin vs Sitagliptin in T2DM with SU+Met Clinical Trial page.